Program
azilsartan medoxomil
Also written as “Azilsartan medoxomil and chlorthalidone”, “Azilsartan medoxomil” and “Azilsartan Medoxomil”.
Its studies are mostly in Essential Hypertension · Hypertension · Renal Insufficiency, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 230 open or running | phase 4since Jun 24, 2015 | Aug 7, 2006 | none ahead |
| Azurity Pharmaceuticals | 10 open or running | phase 3since Sep 8, 2014 | Sep 8, 2014 | none ahead |
| Gedeon Richter Plc. | 11 open or running | phase 1since Apr 28, 2025 | Apr 28, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Aug 7, 2006.
- Jan 7, 2009Phase 3 study in Essential HypertensionTakeda · NCT00818883 · 609 enrolled · United States, Russian Federation
- Feb 13, 20092 phase 3 studiesTakeda · NCT00846365, NCT00847626
- Oct 12, 2009Phase 3 study in Essential HypertensionTakeda · NCT00996281 · 837 enrolled · Austria, Germany, Netherlands and more
- Dec 14, 2009Phase 3 study in Essential HypertensionTakeda · NCT01033071 · 1,071 enrolled · United States, Canada
- Feb 26, 2010Phase 1 study in HypertensionTakeda · NCT01078376 · 29 enrolled · United States, United Kingdom
- Mar 4, 2011Phase 3 study in Renal InsufficiencyTakeda · NCT01309828 · 153 enrolled · Bulgaria, Germany, Latvia and more
- Oct 18, 2011Phase 3 study in Essential HypertensionTakeda · NCT01456169 · 507 enrolled · Bulgaria, Estonia, France and more
- Dec 18, 2011Phase 3 study in HypertensionTakeda · NCT01496430 · 105 enrolled · United States
- Jul 28, 2014Phase 3 study in HypertensionTakeda · NCT02203916 · 328 enrolled · Korea, Republic of
- Sep 8, 2014Azurity Pharmaceuticals’ first study: phase 3 study in HypertensionNew to Azurity PharmaceuticalsAzurity Pharmaceuticals · NCT02235909 · 377 enrolled · United States, Argentina, Brazil and more
- Jun 22, 2015Phase 3 study in Essential HypertensionTakeda · NCT02480764 · 612 enrolled · China
- Jun 24, 2015Phase 4 study in Essential HypertensionTakeda · NCT02517866 · 380 enrolled · China, Taiwan, Thailand
- Sep 2, 2015Phase 1 study in Healthy VolunteerTakeda · NCT02541669 · 64 enrolled · China
- Apr 28, 2025Gedeon Richter Plc.’s first study: phase 1 study in HypertensionNew to Gedeon Richter Plc.Gedeon Richter Plc. · NCT06990204 · 56 planned · Russian Federation
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Valsartanrule | Novartis | phase 4 | 145 |
| Telmisartanrule | Boehringer Ingelheim | phase 4 | 132 |
| Losartanrule | Organon | phase 4 | 58 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06990204Hypertension · Russian Federation | 1 | Not yet recruiting | Gedeon Richter Plc. | Jul 1, 2025 | 56 |
| NCT02541669Healthy Volunteer · China | 1 | Completed | Takeda | Mar 17, 2017 | 64 |
| NCT02517866Essential Hypertension · China, Taiwan, Thailand | 4 | Completed | Takeda | Nov 15, 2016 | 380 |
| NCT02480764Essential Hypertension · China | 3 | Completed | Takeda | Sep 22, 2017 | 612 |
| NCT02235909Hypertension · United States, Argentina, Brazil and more | 3 | Completed | Azurity Pharmaceuticals | Nov 11, 2019 | 377 |
| NCT02203916Hypertension · Korea, Republic of | 3 | Completed | Takeda | Jan 2016 | 328 |
| NCT01496430Hypertension · United States | 3 | Terminated | Takeda | May 2013 | 105 |
| NCT01456169Essential Hypertension · Bulgaria, Estonia, France and more | 3 | Completed | Takeda | Dec 2012 | 507 |
| NCT01309828Renal Insufficiency · Bulgaria, Germany, Latvia and more | 3 | Completed | Takeda | Oct 2012 | 153 |
| NCT01078376Hypertension · United States, United Kingdom | 1 | Terminated | Takeda | Jul 2013 | 29 |
| NCT01033071Essential Hypertension · United States, Canada | 3 | Completed | Takeda | Oct 2010 | 1,071 |
| NCT00996281Essential Hypertension · Austria, Germany, Netherlands and more | 3 | Completed | Takeda | Nov 2011 | 837 |
| NCT00847626Hypertension · United States, Chile, Mexico and more | 3 | Completed | Takeda | May 2010 | 1,711 |
| NCT00846365Essential Hypertension · United States, Chile, Mexico | 3 | Completed | Takeda | Jun 2010 | 1,085 |
| NCT00818883Essential Hypertension · United States, Russian Federation | 3 | Completed | Takeda | Nov 2009 | 609 |
| NCT00760214Hypertension · Bulgaria, Estonia, Finland and more | 3 | Completed | Takeda | Apr 2009 | 885 |
| NCT00696436Hypertension · United States, Argentina, Brazil and more | 3 | Completed | Takeda | Aug 2009 | 1,291 |
| NCT00696384Hypertension · United States, Argentina, Mexico | 3 | Completed | Takeda | Apr 2009 | 418 |
| NCT00696241Hypertension · United States, Argentina, Mexico | 3 | Completed | Takeda | Oct 2008 | 1,275 |
| NCT00695955Hypertension · United States, Chile, Mexico | 3 | Completed | Takeda | May 2010 | 669 |
| NCT00591773Hypertension · United States | 3 | Completed | Takeda | Mar 2009 | 551 |
| NCT00591578Hypertension · United States, Chile, Mexico and more | 3 | Completed | Takeda | Sep 2009 | 984 |
| NCT00591266Hypertension · United States | 3 | Completed | Takeda | Mar 2009 | 566 |
| NCT00591253Hypertension · United States, Puerto Rico | 3 | Completed | Takeda | Apr 2009 | 413 |
| NCT00362115Hypertension · United States, Argentina, Mexico and more | 2 | Completed | Takeda | Dec 2006 | 449 |
How it is read
Names in the registry
- “Azilsartan medoxomil and chlorthalidone”, 15 entries
- “Azilsartan medoxomil”, 14 entries
- “Azilsartan Medoxomil”, 8 entries
- “Azilsartan medoxomil (TAK-491)”, 4 entries
- “Azilsartan medoxomil and olmesartan”, 3 entries
Codes read as this program: AR14, TAK491CLD.
Conditions, from the studies’ own filings
- Essential Hypertension, 12 studies
- Hypertension, 11 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.